Archived Facts

(Reuters) – The Federal Trade Commission said makers of branded drugs that settle patent challenges by promising not to launch their own generic alternatives are using such agreements to delay generic competition.

Popular Posts:

Related Posts:

Leave a Reply

(Reuters) – The Federal Trade Commission said makers of branded drugs that settle patent challenges by promising not to launch their own generic alternatives are using such agreements to delay generic competition.

Popular Posts:

Related Posts:

Leave a Reply